BioRestorative Therapies, Inc. (BRTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 250K 500K 750K Q2 '21: 65K Q3 '21: 58K Q4 '21: 46K Q1 '22: 44K Q2 '22: 100.1K Q3 '22: 121.1K Q4 '22: 119.8K Q1 '23: 135.1K Q2 '23: 128.5K Q3 '23: 130.2K Q4 '23: 145.8K Q1 '24: 149.5K Q2 '24: 174.1K Q3 '24: 377K Q4 '24: 401K Q1 '25: 391K Q2 '25: 605.2K Q3 '25: 383.4K Q4 '25: 359.7K Q1 '26: 357.9K Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Gross Profit TTM

0 200K 400K 600K Q3 '14: 227.7K Q4 '15: 367.4K Q1 '16: 268.1K Q2 '16: 210K Q3 '16: 169.8K Q4 '16: 36.3K Q1 '17: 34.1K Q2 '17: 38.1K Q3 '17: 49.1K Q4 '17: 81K Q4 '23: 145.8K Q1 '24: 149.5K Q2 '24: 167.6K Q3 '24: 352.3K Q4 '24: 372.9K Q1 '25: 360K Q2 '25: 572K Q3 '25: 357.9K Q4 '25: 335.9K Q1 '26: 329.6K Q4 '15 Q3 '16 Q2 '17 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Operating Income TTM

-27M -18M -9M 0 9M 18M 27M Q2 '21: -20.1M Q3 '21: -23.2M Q4 '21: -26.3M Q1 '22: -16.3M Q2 '22: -17.4M Q3 '22: -18.3M Q4 '22: -19M Q1 '23: -19.7M Q2 '23: -18.2M Q3 '23: -16.7M Q4 '23: -15.2M Q1 '24: -13.6M Q2 '24: -12.9M Q3 '24: -12.1M Q4 '24: -11.6M Q1 '25: -12.3M Q2 '25: -13.1M Q3 '25: -14.5M Q4 '25: -15.6M Q1 '26: -14.2M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Net Income TTM

-60M -40M -20M 0 20M 40M 60M Q2 '21: -26.3M Q3 '21: -29.7M Q4 '21: -44.3M Q1 '22: -33.5M Q2 '22: -34.1M Q3 '22: -34.6M Q4 '22: -16.8M Q1 '23: -19.2M Q2 '23: -20.2M Q3 '23: -10.8M Q4 '23: -10.4M Q1 '24: -5.5M Q2 '24: -3.8M Q3 '24: -9.6M Q4 '24: -9M Q1 '25: -12.1M Q2 '25: -10.7M Q3 '25: -12.7M Q4 '25: -14.2M Q1 '26: -11.1M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Cost of Revenue TTM

0 15K 30K 45K Q1 '25: 31K Q2 '25: 33.2K Q3 '25: 25.5K Q4 '25: 23.8K Q1 '26: 28.3K Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26

Operating Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q2 '21: -2.7M Q3 '21: -2.8M Q4 '21: -3.3M Q1 '22: -4.1M Q2 '22: -4.6M Q3 '22: -5.4M Q4 '22: -5.9M Q1 '23: -6.7M Q2 '23: -6.6M Q3 '23: -6.3M Q4 '23: -6.5M Q1 '24: -6.4M Q2 '24: -7.1M Q3 '24: -7.7M Q4 '24: -8.2M Q1 '25: -8.7M Q2 '25: -9.5M Q3 '25: -10.7M Q4 '25: -10.8M Q1 '26: -11.8M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Free Cash Flow TTM

-12M -8M -4M 0 4M 8M 12M Q1 '14: -2.7M Q2 '14: -3M Q3 '14: -3.4M Q4 '14: -3.4M Q1 '15: -3.4M Q2 '15: -3.3M Q3 '15: -3.2M Q4 '15: -3.5M Q1 '16: -4.6M Q2 '16: -4.8M Q3 '16: -5.2M Q4 '16: -5.2M Q4 '22: -6.2M Q1 '23: -6.9M Q2 '23: -6.7M Q3 '23: -6.4M Q4 '23: -6.6M Q2 '25: -9.6M Q3 '25: -10.8M Q4 '25: -10.9M Q2 '14 Q1 '15 Q4 '15 Q3 '16 Q1 '23 Q4 '23 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 600M 1.2B 1.8B Q2 '19: 17.5M Q2 '20: 1.6B Q1 '21: 729.9K Q2 '21: 795.9K Q3 '21: 838.7K Q1 '22: 3.5M Q2 '22: 3.6M Q3 '22: 3.6M Q1 '23: 3.7M Q2 '23: 3.9M Q3 '23: 12.3M Q1 '24: 6.7M Q2 '24: 8.1M Q3 '24: 8.1M Q1 '25: 8.4M Q2 '25: 8.7M Q3 '25: 9.1M Q1 '26: 17.7M Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q2 '20: -0.15 Q3 '20: -2.02 Q4 '20: -14.74 Q1 '22: -14.31 Q2 '22: -15.59 Q3 '22: -11.88 Q4 '22: -5.61 Q1 '23: -5.21 Q2 '23: -5.40 Q3 '23: -3.73 Q4 '23: -2.47 Q1 '24: -0.87 Q2 '24: 0.10 Q3 '24: -0.42 Q4 '24: -1.16 Q1 '25: -1.47 Q2 '25: -1.27 Q3 '25: -1.47 Q4 '25: -1.59 Q1 '26: -1.07 Q3 '20 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.